ASML HOLDING 1 577.800 € (-3,89 %)
DBV TECHNOLOGIES 2.810 € (+0,36 %)
ALFEN 14.630 € (-4,75 %)
SWI CAPITAL 6.300 € (-12,01 %)
AKWEL 6.780 € (+0,30 %)
SCHNEIDER ELECTRIC 275.900 € (-0,27 %)
CAPGEMINI 91.560 € (+0,93 %)
AXA 43.830 € (+0,76 %)
SHELL PLC 33.965 € (+1,10 %)
BOLLORE 4.110 € (+0,74 %)
LAKEFRONT BIOTHER. 26.340 € (+1,31 %)
CREDIT AGRICOLE 17.725 € (+1,40 %)
Coca-ColaEuropacif 93.200 € (+0,65 %)
TRIODOS BANK 26.800 € (0,00 %)
ALSTOM 15.445 € (+2,08 %)
AIRBUS 203.900 € (+2,87 %)
SANOFI 75.250 € (+3,01 %)
BAM GROEP KON 11.970 € (-1,72 %)
BOURSE DIRECT 4.780 € (0,00 %)
SAINT GOBAIN 79.860 € (+1,78 %)
PULLUP ENTERTAIN 7.740 € (-2,15 %)
ASM INTERNATIONAL 937.200 € (-5,62 %)
COMPAGNIE ODET 1 452.000 € (-0,41 %)
PROSUS 37.330 € (-2,91 %)
PLUXEE 11.640 € (+1,66 %)
PUBLICIS GROUPE SA 84.720 € (+0,31 %)
UNILEVER 54.290 € (+1,91 %)
STMICROELECTRONICS 61.780 € (-0,95 %)
BNP PARIBAS ACT.A 102.320 € (+1,15 %)
L'OREAL 387.950 € (+2,00 %)
SOITEC 111.750 € (-4,20 %)
NSI N.V. 17.340 € (+0,58 %)
PARROT 10.460 € (+2,95 %)
ING GROEP N.V. 28.230 € (+2,13 %)
AYVENS 11.810 € (+3,32 %)
ABN AMRO BANK N.V. 37.870 € (+2,27 %)
TOTALENERGIES 66.880 € (+1,46 %)
PERNOD RICARD 63.980 € (+3,23 %)
SAFRAN 353.300 € (+0,97 %)
DANONE 73.960 € (+2,44 %)
THALES 240.400 € (+4,80 %)
LVMH 497.950 € (+3,52 %)
ESSILORLUXOTTICA 175.350 € (+1,36 %)
TKH GROUP 42.880 € (-2,28 %)
EUROFINS SCIENT. 69.140 € (+0,99 %)
MICHELIN 34.720 € (+2,12 %)
ENGIE 27.170 € (+2,34 %)
BE SEMICONDUCTOR 262.000 € (-6,96 %)
X-FAB 7.215 € (-5,00 %)
ARCELORMITTAL SA 55.340 € (+6,34 %)
KERING 252.550 € (+2,77 %)
FLOW TRADERS 25.800 € (-0,08 %)
AMG 32.240 € (-1,59 %)
VINCI 126.900 € (+2,09 %)
WOLTERS KLUWER 57.580 € (+0,66 %)
NN GROUP 76.120 € (+0,40 %)
STELLANTIS NV 5.107 € (-0,74 %)
AHOLD DEL 36.160 € (+2,84 %)
ARCADIS 32.860 € (-0,24 %)
NEXITY 7.955 € (+1,66 %) |
23/06/2026 01:35
DoH and Sanofi Partner to Advance Vaccine InnovationEQS-News: The Department of Health - Abu Dhabi / Key word(s): Contract ABU DHABI, UAE, June 23, 2026 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Sanofi, a worldwide biopharma and vaccines leader, have signed an Memorandum of Understanding and intend to into an agreement to advance their partnership in vaccine innovation and to jointly explore the development of a Vaccine Innovation Centre in Abu Dhabi. The collaboration would strengthen capabilities across AI-enabled vaccine discovery, mRNA research, clinical development and manufacturing, and support regional and global preparedness for future public health challenges. ![]() Operating within Abu Dhabi's Health, Endurance, Longevity, and Medicine (HELM) Cluster, the collaboration intends to bring together scientific research, clinical infrastructure, academic expertise, enabling regulation and advanced manufacturing within a single ecosystem. H.E. Dr. Noura Al Ghaithi, Undersecretary of the DoH, said: "Through our partnership with Sanofi, we are bringing together AI, scientific research, clinical expertise, advanced manufacturing and enabling regulation within a single ecosystem designed to accelerate the journey from discovery to impact. This partnership reflects Abu Dhabi's commitment to creating an environment where innovators can build, test and scale solutions that improve lives, strengthen preparedness and advance health outcomes for communities around the world." Baptiste de Clarens, General Manager Vaccines, Greater Gulf at Sanofi, said: "We are proud to deepen our collaboration with the DoH. Vaccine innovation today is being reshaped by artificial intelligence, by advances in mRNA science, and by new models that connect discovery, development and manufacturing. We look forward to exploring how these capabilities can be brought together to accelerate the journey from discovery to the patients." The planned Vaccine Innovation Centre is expected to strengthen Abu Dhabi's contribution to global health security while supporting the development of local scientific talent, advanced manufacturing capabilities and next-generation vaccine innovation. Through the advancement of vaccine research, development and manufacturing capabilities in the region, the centre will help expand access to advanced vaccines and strengthen preparedness for future public health challenges. The announcement forms part of Abu Dhabi's participation at BIO International Convention 2026, where the emirate is showcasing its intelligent life sciences ecosystem and partnerships across genomics, gene editing, AI-enabled health innovation, advanced therapeutics and rare disease. A key enabler of the emirates intelligent life sciences ecosystem is Abu Dhabi's Health, Endurance, Longevity and Medicine (HELM) Cluster, which connects research, investment, commercialisation and healthcare implementation within a single ecosystem. Photo - https://mma.prnewswire.com/media/2998667/The_Department_of_Health_Abu_Dhabi.jpg ![]()
![]() 23.06.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. 2351462 23.06.2026 CET/CEST Source : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière


